Literature DB >> 12045712

Effect of blood sample handling and reverse transcriptase-polymerase chain reaction assay sensitivity on detection of CK20 expression in healthy donor blood.

Femke Vlems1, Richie Soong, Heleen Diepstra, Cornelis Punt, Theo Wobbes, Karim Tabiti, Goos van Muijen.   

Abstract

Data concerning the specificity of cytokeratin 20 (CK20) as a reverse transcriptase-polymerase chain reaction analysis (RT-PCR) marker to detect disseminated tumor cells in blood are conflicting. Underlying causes for these discrepancies need to be determined to clarify the significance of CK20 detection. Because differences in RT-PCR assays and blood sample handling may be important, their influence on CK20 detection was studied. Using a series of healthy donor blood samples spiked with colon tumor cells, the authors compared the sensitivities of two conventional PCRs with different primer sets and a quantitative LightCycler PCR (Roche Diagnostics GmbH, Penzberg, Germany). Additionally, the influence of sample collection and preparation on assay specificity was studied by examining CK20 expression in the mononuclear cell fraction (MNC) of the first and the second aliquot of blood drawn from healthy donors and in the granulocyte cell fraction. At the concentration of one spiked tumor cell/mL blood, the CK20 detection frequency varied from 17% and 67% for the conventional to 78% for the LightCycler PCR. In the unspiked samples, CK20 was detected in 0% and 8% of the conventional and in 11% of the LightCycler PCR tests. Quantitative analysis revealed that CK20 was expressed at a high level in the granulocyte samples. The results demonstrate that differences in assay sensitivity and sample handling influence CK20 detection in blood.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045712     DOI: 10.1097/00019606-200206000-00005

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  6 in total

1.  Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method.

Authors:  Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  Molecular detection of disseminated tumor cells in the peripheral blood in patients with gastrointestinal cancer.

Authors:  Peilin Huang; Jingmei Wang; Ying Guo; Wei Xie
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-18       Impact factor: 4.553

3.  Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients.

Authors:  Nadia Dandachi; Marija Balic; Stefanie Stanzer; Michael Halm; Margit Resel; Thomas Anton Hinterleitner; Hellmut Samonigg; Thomas Bauernhofer
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

4.  Heterogeneous detection of circulating tumor cells in patients with colorectal cancer by immunomagnetic enrichment using different EpCAM-specific antibodies.

Authors:  Dalibor Antolovic; Luis Galindo; Anina Carstens; Nuh Rahbari; Markus W Büchler; Jürgen Weitz; Moritz Koch
Journal:  BMC Biotechnol       Date:  2010-04-28       Impact factor: 2.563

Review 5.  Clinical relevance associated to the analysis of circulating tumour cells in patients with solid tumours.

Authors:  María José Serrano Fernádez; Juan Carlos Alvarez Merino; Iñigo Martínez Zubiaurre; Ana Fernández García; Pedro Sánchez Rovira; José Antonio Lorente Acosta
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

6.  Quantitative real-time RT-PCR of disseminated tumor cells in combination with immunomagnetic cell enrichment.

Authors:  Silke Lankiewicz; Bertha Gutierrez Rivero; Oliver Bócher
Journal:  Mol Biotechnol       Date:  2006-09       Impact factor: 2.860

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.